Joe Biden has ordered nearly all healthcare insurers across the country to make PrEP readily available at no cost to the public.
Joe Biden has ordered nearly all healthcare insurers across the country to make PrEP readily available at no cost to the public.
Commonly used HIV drug being tested in COVID-19 trials
Landmark court ruling could be game changer for costings of PrEP and other HIV drugs. A ruling today from the European Court of Justice (ECJ) suggests that Gilead’s patent for Truvada, the drug used to treat many people living with HIV, and the drug used for PrEP, may be under threat.
Pre-exposure prophylaxis (PrEP) will be available through the NHS from September, as part of a three-year trial. The announcement comes a year and a day after an historic win for NAT (National AIDS Trust) at the High Court that confirmed the NHS’s legal ability to fund the drug, which stops people from getting HIV.
Following a rigorous process, the Scottish Medicines Consortium (SMC) announce that PrEP, the HIV prevention drug, has been deemed a cost-effective treatment to prevent the transmission of HIV in Scotland.
News that NHS England is to fund a PrEP clinical trial for 10,000 people over next 3 years costing £10million receives cautious welcome. NHS England agrees to extend national HIV prevention programme with Public Health England.
While UK authorities drag their heels on a decision to make Prep available to people most at risk of acquiring HIV, Norway provides a stark contrast and agrees to fund the drug.
NHS England confirms decision not to fund PrEP following a meeting of its Specialised Services Commissioning Committee on May 31. 2016.
Decision by NHS England to shelve plans to make PrEP available on National Health is “shameful”, says CEO of Terrence Higgins Trust.
Central North West London (CNWL), NHS Foundation Trust add their voice to calls for once-a-day drug to prevent HIV infection be offered on the NHS.
